A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus

Hepatology

Volumn 30, Issue 2, 1999, Pages 531-536

  Heaihcote, Jenny ^a   McHutchison, John ^b   Lee, Samuel ^c   Tong, Myron ^d   Benner, Kent ^e   Minuk, Gerald ^f   Wright, Teresa ^g   Fikes, John ^h   Livingston, Brian ^h   Sette, Alex ^h   Chestnut, Robert ^h  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b SCRIPPS CLINIC   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d HUNTINGTON MEMORIAL HOSPITAL   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY OF MANITOBA   (Canada)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h Epimmune   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CY 1899; EPITOPE; HEPATITIS B SURFACE ANTIGEN; HLA ANTIGEN CLASS 1; LIPOPEPTIDE; PALMITIC ACID; UNCLASSIFIED DRUG; VACCINE; VIRUS DNA;

ADULT; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SKIN MANIFESTATION; VACCINATION;

ADULT; AGED; AMINO ACID SEQUENCE; EPITOPES, T-LYMPHOCYTE; FEMALE; HEPATITIS B CORE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; IMMUNIZATION; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PALMITIC ACID; PILOT PROJECTS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL VACCINES;

EID: 0032769963     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510300208     Document Type: Article

References (20)

1. Seeff LB, Beebe GW, Hoofnagle JH, Norman JE, Buskell-Bates Z, Waggoner JG, Kaplowitz N, et al. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States. N Engl J Med 1987;316:966-970.
2. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975;292:771-774.
3. Beasley RP, Hwang LY. Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J Infect Dis 1983;147:185-190.
4. Lok AS, Lai CL. Acute exacerbations in chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol 1990;10:23-44.
5. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterology 1991;100:182-188.
6. Penna A, Chisari FV, Bertoletti A, Missale G, Fowler P, Guiberti T, Fiaccadori F, et al. Cytotoxic T lymphocyte recognize an HLA-A2 restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991;174:1565-1570.
7. Ferrari C, Penna A, Guiberti T, Tong MJ, Ribera E, Fiaccadori F, Chisari FV. Intrahepatic nucleocapsid antigen-specific T cells in chronic active hepatitis B. J Immunol 1987;139:2050-2058.
8. Rehermann B, Fowler P, Sidney J, Person J, Redeker A, Brown M, Moss B, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995;181:1047-1058.
9. Bertoletti A, Ferrari C, Ficcadori F, Penna A, Margolskee R, Schlicht HJ, Fowler P, et al. HLA class I-restricted human cytotoxic T cells recognized endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci U S A 1991;88:10445-10449.
10. Nayersina R, Fowler P, Guilhot S, Missale G, Cerny A, Schlicht HJ, Vitiello R, et al. HLA-A2 restricted cytotoxic T lymphocytes response to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 1993;150:4659-4671.
11. Rehermann, B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996;97:1655-1665.
12. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;102:968-975.
13. Guidotti LG, Ando K, Hobbs MV, Ishikawa T, Runkel L, Schreiber RD, Chisari FV. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A 1994;91:3764-3768.
14. Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, Yuan L, et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. J Clin Invest 1995;95:341-349.
15. Celis E, Tsai V, Crimi C, DeMars R, Wentworth PA, Chesnut RW, Grey HM, et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci U S A 1994;91:2105-2109.
16. Livingston BD, Crimi C, Grey H, Ishioka G, Chisari FV, Fikes J, Grey H, et al. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J Immunol 1997;1383-1392.
17. Lau GK, Lok AS, Liang RH, Lai CL, Chiu EK, Lau YL, Lam SK. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. HEPATOLOGY 1997;25:1497-1501.
18. Livingston BD, Alexander J, Crimi C, Celis E, Daly K, Guidotti LG, Chisari FV, et al. Altered helper T lymphocytes function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J Immunol 1999;162:3088-3095.
19. Artillo S, Pastore G, Alberti A, Milella M, Santantonio T, Fattovich G, Guistina G, et al. Double-blind randomized trial of interleukin-2 treatment of chronic hepatitis B. J Med Virol 1998;54:167-172.
20. Ishioka GY, Fikes J, Hermanson G, Livingston B, Crimi C, Del Guercio MF, Oseroff C, et al. Utilization of MHC class 1 transgenic mice for the development of minigene vaccines encoding multiple HLA-restricted CTL epitopes. J Immunol 1999;162:3915-3925.